Biogen updates Phase III AD studies

EVP and CMO Alfred Sandrock from Biogen Inc. (NASDAQ:BIIB) said the company will enroll a total of an additional 510 patients in the Phase III ENGAGE and EMERGE

Read the full 285 word article

User Sign In